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A B S T R A C T
Triple-negative breast cancers (TNBCs) are among the most aggressive cancers characterized by a high
propensity to invade, metastasize and relapse. We previously reported that the TNBC-speciﬁc inhibitor,
AMPI-109, signiﬁcantly impairs the ability of TNBC cells to migrate and invade by reducing levels of the
metastasis-promoting phosphatase, PRL-3. Here, we examined the mechanisms by which AMPI-109 and
loss of PRL-3 impede cell migration and invasion. AMPI-109 treatment or knock down of PRL-3 expres-
sion were associated with deactivation of Src and ERK signaling and concomitant downregulation of RhoA
and Rac1/2/3 GTPase protein levels. These cellular changes led to rearranged ﬁlamentous actin net-
works necessary for cell migration and invasion. Conversely, overexpression of PRL-3 promoted TNBC
cell invasion by upregulating matrix metalloproteinase 10, which resulted in increased TNBC cell ad-
herence to, and degradation of, the major basement membrane component laminin. Our data demonstrate
that PRL-3 engages the focal adhesion pathway in TNBC cells as a key mechanism for promoting TNBC
cell migration and invasion. Collectively, these data suggest that blocking PRL-3 activity may be an ef-
fective method for reducing the metastatic potential of TNBC cells.
© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Breast cancer is the principle cause of cancer-related mortality
in women worldwide [1]. Gene expression proﬁling has clustered
the disease into ﬁve major subtypes based on estrogen receptor (ER)
expression, progesterone receptor (PR) expression and human epi-
dermal growth factor receptor 2 (HER2) ampliﬁcation [2]. Anti-
hormonal therapies are available for breast cancer patients with
tumors expressing ER or PR, while targeted therapy with the mono-
clonal antibodies trastuzumab and pertuzumab are indicated for
patients with tumors exhibiting HER2 ampliﬁcation. Unfortu-
nately, triple-negative breast cancers (TNBCs), which comprise 15–
20% of all newly diagnosed cases of breast cancer and are frequently
diagnosed as high grade invasive tumors, lack expression of these
three molecular markers [3]. As a result, cytotoxic chemotherapy
is most frequently utilized as the standard of care for women di-
agnosed with metastatic TNBC and there are currently no approved
targeted agents for these patients. Metastatic TNBC tumors also have
a higher risk of distant recurrence and death compared to other
breast cancers [4]. Paradoxically, patients with non-metastatic TNBC
treated with neoadjuvant chemotherapy have better response rates
than other breast cancer subtypes [5], suggesting a relative driver
of poor outcome in TNBC is the development of metastatic disease.
It is therefore critical to identify new therapeutic agents that can
either slow or prevent the metastatic dissemination of TNBC cells.
Our laboratory previously examined the effects of the novel TNBC-
speciﬁc small molecule inhibitor AMPI-109 on TNBC cell migration
and invasion [6]. Our studies revealed that AMPI-109 has a marked
ability to block TNBC cell migration and invasion, attributable in-
part to its ability to downregulate levels of themetastasis-promoting
phosphatase, PRL-3 [6]. We found that AMPI-109 treatment, knock
down of PRL-3 or catalytic impairment of PRL-3 activity, blocked
the ability of TNBC cells to migrate, whereas overexpression of PRL-3
markedly enhanced both the rate and absolute degree of cell mi-
gration in a scratch-wound assay [6]. Moreover, we demonstrated
that PRL-3 exerted analogous effects on TNBC cell invasion through
Matrigel [6]. These studies suggest that PRL-3 is involved in con-
trolling precursor events for TNBC metastasis. However, the
molecular mechanism for how PRL-3 promotes the motility and in-
vasiveness of TNBC cells is unclear.
In order to metastasize, cancer cells must lose attachment with
neighboring tumor cells and adopt the ability to migrate, attach to,
and invade through the epithelial basement membrane. This is a
complex process primarily orchestrated through the formation,
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stabilization and remodeling of focal adhesion (FA) complexes com-
posed of integrins, Src, FAK, ERK and numerous adaptor proteins
and downstream effectors, such as RhoGTPases, that collectively reg-
ulate epithelial-to-mesenchymal transition (EMT) and trigger
activation of cell migration and invasion programs [7,8]. Assembly
and disassembly of FA sites within invadopodia control cell migra-
tion and invasion by mediating actin assembly and contraction,
thereby promoting cell adhesion to various extracellular sub-
strates on which cancer cells can migrate on or invade through [7,8].
Therefore, the identiﬁcation of key regulators to FA site signaling
is critical in order to determine strategies to prevent activation of
these metastatic-enabling properties.
Here, we describe PRL-3 modulation of the FA pathway as a po-
tential mechanism by which PRL-3 controls these pro-metastatic
phenotypes. Altering PRL-3 expression had a signiﬁcant impact both
on protein expression and on activation levels of a number of FA
pathway effectors, including the proto-oncogene tyrosine-protein
kinase, c-src (Src), ERK, and several RhoGTPases involved in actin
cytoskeletal restructuring.We also investigated the role of thematrix
metalloproteinase (MMP), MMP-10, which we identiﬁed as being
upregulated following overexpression of PRL-3.We found that MMP-
10 upregulation following forced PRL-3 overexpression coincides
with preferential TNBC cell attachment to and degradation of laminin,
which is a major basement membrane component in breast tissue
and a selective substrate for degradation by MMP-10. Moreover,
PRL-3 overexpressing TNBC cells were capable of invading through
laminin-rich Matrigel through an MMP-10 dependent mechanism.
Collectively, these data represent newmolecular insight on how
PRL-3 activates cell migration and invasion programs in TNBC as
precursor events tometastasis – themajor driver of TNBC-associated
deaths.
Materials and methods
Materials
AMPI-109 was synthesized as previously described [9].
Plasmids, transfection and viral transduction
PRL-3 cDNA expression vector was purchased from Origene (Cat. # SC308739).
Transfections were carried out using Mirus TransIT LT1 reagent according to man-
ufacturer’s instructions (Mirus Bio). Individual pLKO.1 lentiviral shRNA clones were
purchased from the University of Colorado Cancer Center Functional Genomics Shared
Resource. The RNAi Consortium identiﬁers are: TRCN0000010661 (shPRL-3 #1),
TRCN0000355597 (shPRL-3 #2), TRCN0000378843 (shMMP-10 #1), and
TRCN0000372935 (shMMP-10 #2). Transduced cells were selected in a medium
containing 2.5 μg/mL puromycin. Speciﬁcity of PRL-3 knock down was determined
by qRT-PCR. Both PRL-3 shRNAs (#1 and #2) exerted speciﬁc knock down of PRL-3
and did not reduce RNA levels of either PRL-1 or PRL-2.
Cell culture and immunoblot analysis
Cell lines were obtained from the University of Colorado Cancer Center Tissue
Culture Shared Resource. BT-20 and MDA-MB-468 cells were cultured in DMEM/F-
12 medium (Corning #10-092-CV) containing 10% fetal bovine serum. SUM-159 cells
were cultured in HAM’s F-12 medium (Corning #10-080-CV) containing 5% fetal
bovine serum, 1 μg/mL hydrocortisone and 5 μg/mL insulin. All cell lines were au-
thenticated by short tandem repeat DNA proﬁling performed by the UCCC DNA
Sequencing and Analysis Core. Western blot analysis was conducted according to
our previous protocol [10]. Antibodies used in the study were: PRL-3 (Cat. # ab82568,
Abcam), p-Src (Y416) (Cat. #2101, Cell Signaling), Src (36D10) (Cat. #2109, Cell Sig-
naling), p-ERK 1/2 (T202/Y204) (Cat. #4377, Cell Signaling), ERK 1/2 (44/42) (Cat.
#4695, Cell signaling), RhoA (67B9) (Cat. #2117, Cell Signaling), Rac1/2/3 (Cat. #2465,
Cell Signaling), MMP-10 (Cat. #SC-9941, Santa Cruz), and β-actin (Cat. # A5441,
Sigma-Aldrich).
Immunoﬂuorescence analysis
Immunoﬂuorescence staining was performed as previously described [11] using
green Alexa Fluor 488 phalloidin staining for F-actin (Cat. #A12379, Thermo Fisher),
β-actin antibody for both ﬁlamentous andmonomer actin forms (Cat. # A5441, Sigma-
Aldrich) and nuclear DAPI stain (Cat. #P-36931, Thermo Fisher).
MMP array
A humanMMP antibody array kit was purchased from Abcam (Cat. # ab134004).
BT-20 cells were transiently transfected with PRL-3 cDNA expression vector 48 hours
prior to cell lysis and the array developed according to the manufacturer’s proto-
col. Membranes were developed using enhanced chemiluminescence (Perkin Elmer)
and autoradiography.
Cell adhesion and spreading assay
We utilized the impedance-based xCELLigence Real-Time Cell Analysis system
(ACEA Biosciences) for the detection of BT-20 and SUM159 TNBC cell adhesion and
spreading on the following substrates: Laminin (Cat. #L4544, Sigma-Aldrich), Elastin
(Cat. #E1625-5G, Sigma-Aldrich), Fibronectin (Cat. #F1141, Signa-Aldrich) and Col-
lagen (Cat. #C2124, Sigma-Aldrich). Brieﬂy, each substrate was diluted to 10 μg/
mL in appropriate TNBC cell media and added to wells on a 96X E-Plate (ACEA
Biosciences) and incubated for 1 hour at 37 °C. The coated plates were then washed
with PBS and incubated in 0.5% BSA solution in PBS for 20 minutes at 37 °C. Wells
were washed again with PBS and 5000 cells were added per well. Cell adhesion and
spreading was measured as changes in impedance with the RT-CES system every 3
minutes for 3 hours. The assay expresses impedance in arbitrary cell index (AU) units.
The cell index at each time point is deﬁned as (Rn−Rb)/15; where Rn is the cell-
electrode impedance of the well when it contains cells and Rb is the background
impedance of the well with the media alone.
Cell invasion assay
Cell invasion was assessed by IncuCyte Zoom Kinetic Live Cell Imaging (Essen
BioScience). 96 well ImageLock Plates (Essen Bioscience) were coated overnight with
100 μg/mL Matrigel Basement Membrane Matrix (Cat. # 356231, Corning). The fol-
lowing day, Matrigel was aspirated and 25,000 cells were plated per well and allowed
to adhere prior to making a scratch with the 96-pin WoundMaker (Essen Biosci-
ence). 50 μL of Matrigel Matrix (8 mg/mL) was then added to the wells, and covered
in 100 μL media containing the appropriate treatments (refer to Fig. 6 legend for
details). Migration and invasion were quantiﬁed using the “Relative Wound Density”
metric generated by IncuCyte software.
Reverse phase protein array analysis
The results outlined in Table 1 are in whole or part based upon data generated
by the TCGA Research Network: http://cancergenome.nih.gov/. Protein expression
values from the “Provisional TCGA Invasive Breast Carcinoma” dataset as assessed
by the reverse phase protein array (RPPA) tool on the Memorial Sloan-Kettering
Cancer Center’s cBio Cancer Genomics Portal. Protein expression values are indi-
cated by the Z-score (mean RPPA score/std) and were obtained using a Z-score
threshold of +/− 2.0.
Results
PRL-3 copy number ampliﬁcation positively correlates with high
levels of Src protein in human breast cancers
To identify PRL-3 associated pathways potentially involved inmi-
gration and invasion phenotypes, we analyzed the provisional cancer
genome atlas (TCGA) invasive breast carcinoma cohort and looked
Table 1
Protein expression changes in invasive human breast carcinoma samples exhibit-
ing PRL-3 copy number ampliﬁcation (>2 copies). Signiﬁcance values were calculated
based on Student’s t-test.
Protein Expression Z-score (RPPA)
Protein PRL-3
Unaltered
PRL-3
Ampliﬁed
P-value
AR 0.15 −0.47 8.33E-08
GATA3 0.12 −0.37 3.15E-05
ESR1 0.11 −0.32 2.41E-04
PRKAA1 0.09 −0.28 3.48E-04
STK11 0.09 −0.28 3.00E-03
BCL2 0.08 −0.25 3.00E-03
MAPK9 0.08 −0.25 4.00E-03
PGR 0.07 −0.22 7.00E-03
SRC −0.08 0.23 6.00E-03
CCNE1 −0.08 0.25 4.00E-03
SYK −0.09 0.26 2.00E-03
CCNB1 −0.10 0.29 3.35E-04
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for proteins with expression patterns that correlated with PRL-3 am-
pliﬁcation. We reasoned that the identiﬁcation of proteins
upregulated along with PRL-3 might lead to the discovery of path-
ways converging with PRL-3 signaling. We identiﬁed a number of
proteins that were either downregulated or upregulated with PRL-3
ampliﬁcation in human breast tumors, including Src (Table 1).
Src is the prototypic member of a family of non-receptor tyro-
sine kinases that play critical roles in signal transduction pathways
involved with cell proliferation, differentiation, survival, motility and
invasion [12–18]. Considering the aberrant activation of Src in a
number of cancer types including breast cancer, drug therapy aimed
at inhibiting Src and/or some of its downstream effectors is con-
sidered to be a potentially useful and promising clinical strategy
[19–25]. Therefore, we sought to determinewhether AMPI-109 treat-
ment or PRL-3 knock down alter Src expression and/or activity in
TNBC cells.
AMPI-109 treatment and knock down of PRL-3 reduces Src, ERK
signaling
Src is activated at FA sites following engagement by a variety of
different cellular receptors including immune response receptors,
integrins, receptor tyrosine kinases, G protein-coupled receptors as
well as cytokine receptors [12–18]. The recruitment of Src to integrin
complexes at FA sites, for example, is thought to lead to auto-
phosphorylation of Src at tyrosine 416 (Y416). Activated Src plays
a number of direct and indirect roles at activating downstream path-
ways, including ERK, for propagating changes in cytoskeletal
organization necessary for cell motility. Indeed, studies have dem-
onstrated that Src-mediated migration and invasion of breast cancer
and hepatocellular carcinoma cells is controlled through down-
stream activation of the ERK pathway [26–28]. Therefore, we treated
BT-20 and MDA-MB-468 TNBC cells with AMPI-109 or transduced
cells with two different shRNAs to PRL-3 and examined Src and ERK
activation (phosphorylation) by immunblot analysis.
We observed that AMPI-109 signiﬁcantly blocked activation of
Src at tyrosine 416 (Y416) and ERK at threonine 202 and tyrosine
204 (T202/Y204) (Fig. 1). We also observed decreases in total levels
of Src and ERK with AMPI-109 treatment. Additionally, knock down
of PRL-3 resulted in deactivation of Src and ERK signaling, but in
contrast to AMPI-109 treatment, largely had no effect on total levels
of Src or ERK in BT-20 cells suggesting other targets for AMPI-109
likely exist (Fig. 1).
Knock down of PRL-3 or treatment with AMPI-109 decreases RhoA
and Rac1/2/3 GTPase levels and associates with remodeling of actin
networks in TNBC cells
We next determined whether AMPI-109 and PRL-3 also affect
common FA site transducers, downstream of Src and ERK.
RhoGTPases function as downstream mediators of the FA site and
are responsible for executing changes in the actin cytoskeleton that
lead to cell restructuring and migration [29–34]. We observed de-
creases in RhoA and Rac1/2/3 RhoGTPase levels following knock
down of PRL-3 or AMPI-109 treatment (Fig. 2A). We did not observe
changes in Cdc42, RhoB or RhoC (data not shown). Additionally,
knock down of PRL-3 and AMPI-109 treatment led to a signiﬁcant
reduction of ﬁlamentous actin (F-actin) networks as determined by
phalloidin staining (Fig. 2B). Conversely, overexpression of PRL-3 lead
to moderate cytoplasmic F-actin staining and pronounced clus-
ters of actin that spatially coincided with regions of membrane
extension or protrusion.
Collectively, these data indicate that AMPI-109 and PRL-3 impinge
on FA members and RhoGTPase networks to alter physical cellular
components, such as F-actin, that are necessary for cell migration.
These data suggest that PRL-3 may also then play a key role in con-
trolling the cells ability to adhere to the extracellular matrix (ECM)
– as changes in the internal cytoskeleton would likely inﬂuence ex-
tracellular adhesion dynamics.
PRL-3 overexpression increases levels of MMP-10 and promotes TNBC
cell invasion by enhancing adhesion to and degradation of laminin
Understanding tumor cell adhesion to ECM substrates is criti-
cal in order to identify how cancer cells breach the basement
membrane and invade neighboring normal tissue to metastasize.
Migrating cells rely on attachment to the ECM via formation and
maintenance of integrin clusters at FA sites. Collectively, these FA
sites mediate attachment to basement membrane substrates such
as laminin, elastin, collagen and ﬁbronectin and serve as anchor or
attachment points for migrating cells. This interaction incorpo-
rates extracellular mechanical contact with the substrate as a trigger
event for intracellular signaling networks, such as Src, ERK and
RhoGTPases [35]. In this regard, cell attachment to a speciﬁc sub-
strate is important for spatial orientation of epithelial cells and serves
as a general “sensor” for the cells local environment. In order for
cells to invade through their speciﬁc substrate environment, MMPs
need to be expressed and activated to degrade the substrate [36].
Because we have observed that PRL-3 is involved in manipulating
intracellular pathways activated by FA contact with the ECM, a key
mechanistic question is whether increased PRL-3 expression alters
the ability of TNBC cells to adhere to and degrade particular ECM
substrates.
To examine this, we overexpressed PRL-3 in BT-20 TNBC cells
in order to identify MMPs potentially associated with the PRL-3
signaling axis. Utilizing a human MMP protein array, we identi-
ﬁed a list of MMPs, whose total protein expression levels changed
in response to PRL-3 overexpression (Fig. 3A). These data sug-
gested that MMP-10, the most highly upregulated MMP after PRL-3
overexpression, may be one critical MMP secreted to act upon and
degrade the ECM. Interestingly, the preferred non-collagen type
Fig. 1. AMPI-109 treatment and PRL-3 knock down inactivate Src, ERK signaling in
TNBC cells. Immunoblot analysis of changes in activation of Src and ERK proteins
as assessed by phosphorylation of Src at tyrosine 416 (Y416) and ERK at threonine
202 (T202) and tyrosine 204 (Y204) in vehicle control (EtOH) or AMPI-109 (100 nM)
treated BT-20 and MDA-MB-468 TNBC cells. Right panels for each cell line depict
changes in Src and ERK activation in PRL-3 knock down (shPRL-3 #1 and shPRL-3
#2) compared to non-silencing control cells (pLKO). The experiment was repeated
twice and representative images shown.
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IV substrates for MMP-10 include laminin, ﬁbronectin and elastin
(Fig. 3B) suggesting that BT-20 cells may preferentially adhere to
and degrade one or more of these three ECM components to facil-
itate cell invasion.
We therefore characterized the ability of BT-20 cells to adhere
to and spread on each of these three substrates. We pre-coated cell
culture plates with elastin, laminin and ﬁbronectin matrix and
allowed BT-20 cells to adhere to each. We monitored cell attach-
ment and extent of cell spreading on the various substrates by
utilizing the real-time dynamic xCELLigence impedance-based ad-
hesion and spreading platform.We observed that BT-20 cells exhibit
a diverse adhesion proﬁle to each of the three substrates (Fig. 4A).
Fibronectin was the least preferred non-collagen substrate for BT-
20 attachment, while elastin and laminin exhibited similar degrees
of spreading at 2 hours. Interestingly, BT-20 cells contracted or de-
creased in size when initially exposed to laminin as indicated by
the negative cell index values between 0.5 and 1 hours, but then
recovered and increased their spreading capacity on laminin at a
higher rate relative to elastin (Fig. 4A) – reaching equivalent im-
pedance to elastin at 2 hours.
We next examined the effects of overexpressing PRL-3 on cell
attachment to each of these three substrates (Fig. 4B). By doing so,
we reasoned that wemay identify differences in binding to speciﬁc
substrates, reﬂecting on key aspects of PRL-3 biology. We observed
that overexpression of PRL-3 (pcDNA-PRL-3) in BT-20 cells had no
effect on the extent of cell attachment or spreading when exposed
to ﬁbronectin. However, these cells did appear to requiremore time
sensing the local ECM environment before attaching and spreading
Fig. 2. Knock down of PRL-3 and treatment with AMPI-109 alters RhoGTPase expression and ﬁlamentous actin structure. (A) Western blot of BT-20 TNBC cells transduced
with non-silencing control (pLKO) or shRNA to PRL-3 (shPRL-3 #1), or treated with vehicle control (EtOH) or AMPI-109 (100 nM) for 6 hours. Individual panels represent
PRL-3 protein, RhoA, Rac1/2/3 and β-actin protein levels. (B) Immunoﬂuorescence images of BT-20 cells transduced with non-silencing control (pLKO), PRL-3 shRNA (shPRL-3
#1), treated with vehicle control (EtOH), AMPI-109 (100 nM) or transiently transfected with scrambled DNA (Ctl) or PRL-3 expression vectors (pcDNA-PRL-3). F-actin (green)
represents ﬁlamentous actin as determined by phalloidin staining. β-actin (red) represents the total actin monomer pool using an antibody toβ-actin. DAPI = blue. The ex-
periment was repeated twice and representative images shown.
Fig. 3. Overexpression of PRL-3 alters MMP levels in BT-20 TNBC cells. (A) BT-20 cells were transiently transfected with an expression vector encoding PRL-3 (pcDNA-PRL-
3) or scrambled control (pcDNA). Percent change in MMP expression from pcDNA control baseline depicted. (B) Table indicating the locations and substrate activities of
MMPs.
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(Fig. 4C; 1 versus 0.5 hours). In contrast, BT-20 cells overexpressing
PRL-3 exhibited a modest and improved ability to adhere to and
spread on elastin (Fig. 4D). Overexpression of PRL-3 in BT-20 cells
exposed to laminin, however, signiﬁcantly enhanced both the rate
andmagnitude of cell adhesion and spreading (Fig. 4E), strongly sug-
gesting that PRL-3 functions to enhance BT-20 cell attachment to
laminin, one of the most abundant ECM component in the basal
lamina of human breast tissues.
To further study the relationship between PRL-3 and TNBC cell
attachment to laminin, we examined the effect of PRL-3 knock down
in a TNBC cell line with high PRL-3 levels, SUM159 (Fig. 5A). Spe-
ciﬁcally, we were interested in examining whether reducing PRL-3
levels would reverse cell attachment to laminin. Interestingly, control
SUM159 TNBC cells exhibited a similar preference pattern for ECM
substrate binding as BT-20 cells with respect to laminin and elastin,
but also ﬁbronectin (Fig. 5B).
Following knock down of PRL-3 in SUM159 cells, we observed
no changes in binding proﬁles to ﬁbronectin (Fig. 5C) or elastin
(Fig. 5D) but did observe, as hypothesized, a substantial impair-
ment in the binding aﬃnity and spreading on laminin (Fig. 5E).
We previously reported a role for PRL-3 in enhancing TNBC cell
invasiveness through Matrigel [6]. Here, we demonstrate a poten-
tially important role for TNBC cell interaction with a key basement
membrane substrate, laminin. By knocking down PRL-3 in SUM159
cells, invasive potential could be diminished, and conversely, by
overexpressing PRL-3 in BT-20 cells, invasion rate and absolute degree
could be signiﬁcantly enhanced [6]. However, these data did not take
into account the identiﬁcation of MMP-10 as being important for
PRL-3 activity.
Therefore, we chose to examine the effects of knocking down
MMP-10 on SUM159 cell invasion, reasoning that it would pheno-
copy the effect of knocking down PRL-3. We observed a reduction
in the ability of SUM159 cells to invade throughMatrigel after knock-
ing down MMP-10 using two different shRNAs (Fig. 6A,B), thus
phenocopying the effects of knocking down PRL-3 [6]. However, since
overexpression of PRL-3 upregulates MMP-10, and MMP-10 exerts
speciﬁc action on degrading laminin, a key question is whether knock
down of MMP-10 could reverse the invasive potential driven by PRL-3
overexpression. After conﬁrming that overexpression of PRL-3 en-
hances BT-20 cell invasion (Fig. 6C), we chose to overexpress PRL-3
in BT-20 cells with MMP-10 knocked down. PRL-3 was not as ef-
fective in driving cell invasion in the absence of MMP-10 (Fig. 6C),
suggesting that PRL-3 driven invasiveness is mediated, at least in
part, through MMP-10 activity.
Fig. 4. BT-20 TNBC cells preferentially adhere to and spread on elastin and laminin basement membrane substrates. (A) BT-20 cells transfected with empty cDNA expres-
sion vector (Ctl) were plated in suspension and allowed to adhere to plates pre-coated with elastin (red), laminin (green) or ﬁbronectin (blue). (B) BT-20 cells were transfected
with PRL-3 cDNA expression vector (pcDNA-PRL-3) or empty vector (Ctl) and immunoblots analysis performed 24 hours after transfection. Individual panels represent PRL-3
protein and β-actin protein levels. (C–E) BT-20 cells transfected with PRL-3 cDNA (pcDNA-PRL-3; blue, same cells as in (A)) or empty vector (Ctl; red) were plated in sus-
pension and allowed to adhere to ﬁbronectin (C), elastin (D) or laminin (E). Each substrate was plated at 10 μg/mL and cell impedance was monitored for 2 hours after
plating. *p = <0.05 as determined by Student’s t-test on last time-point. The experiments were repeated three times.
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Discussion
There is currently a pressing need to understand which signal-
ing pathways promote TNBC cell migration and invasion so that new
strategies aimed at targeting key regulators of these processes may
be identiﬁed for therapeutic exploitation. PRL-3 was ﬁrst identi-
ﬁed as a metastasis-associated phosphatase through studies that
demonstrated high PRL-3 levels in metastatic colorectal carcino-
ma samples, but low in non-metastatic colorectal carcinoma or
normal colonic epithelial cells [37]. Similarly, our immunohisto-
chemical evaluation of human breast cancers revealed that PRL-3
expression positively correlates with regional disease and distant
metastases in TNBC [6]. However, a mechanistic explanation for how
PRL-3 promotes acquisition of migratory and invasive programs es-
sential for TNBC metastasis remained unclear.
Here, we describe a relationship between PRL-3 and activation
of the FA Src-ERK pathway. Our data augment existing reports that
indicate Src is preferentially localized and active at the cell plasma
membrane in TNBCs versus other breast cancer subtypes [38] and
that basal and TNBC tumors exhibit sensitivity to dasatinib, an orally
bioavailable inhibitor of Src and abl kinases [39]. While the direct
link between PRL-3 and the Src-ERK pathway remains unknown,
these data strongly suggest theremay be rationale for exploring com-
binatorial inhibition of Src and PRL-3 in TNBC models of migration
and invasion to reduce metastatic potential.
We also discovered that changes in PRL-3 expression, or AMPI-
109 treatment, exert an inﬂuence on protein expression levels of
downstreammembers in the FA pathway, including RhoA and Rac1/
2/3. These data are important because RhoGTPases are keymediators
in the control of actin nucleation, ﬁlament assembly, stabilization
and disassembly, mechanically controlling the cells ability tomigrate
and invade by forming cell protrusions or invadopodia. Indeed, co-
inciding with the decrease in RhoA and Rac1/2/3 expression after
PRL-3 knock downwas the absence of a detectable ﬁlamentous actin
network. These data suggest that one terminal effect of PRL-3 knock
down or AMPI-109 treatment, mediated through the FA Src-ERK-
RhoGTPase pathway may be the disruption of actin assembly,
extension or stabilization thereby eliminating the necessary “hard-
ware” or infrastructure for TNBC cells to migrate and invade.
Because cancer cells must also degrade the local basement mem-
brane to metastasize, we expanded our analysis on the role of PRL-3
in the metastatic cascade by studying the impact PRL-3 expres-
Fig. 5. SUM159 TNBC cells preferentially adhere to, and spread on, elastin, ﬁbronectin and laminin basement membrane substrates. (A) PRL-3 levels following transduc-
tion of SUM159 cells with non-silencing control (pLKO) or PRL-3 shRNA (shPRL-3 #1) were assessed by immunoblot. (B) SUM159 pLKO cells were plated in suspension and
allowed to adhere to elastin (green), ﬁbronectin (brown) or laminin (dark green). (C–E) SUM159 cells were transduced with non-silencing control shRNA (pLKO; Same cells
as in (B)) or shRNA to PRL-3 (shPRL-3 #1) and selected for three days prior to being plated in suspension and allowed to adhere to ﬁbronectin (C), elastin (D) or laminin (E).
Each substrate was plated at 10 μg/mL and cell impedance was monitored for 3.5 hours after plating. *p = <0.05 as determined by Student’s t-test on last time-point. The
experiments were repeated three times.
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sion has on TNBC cell speciﬁcity for adhesion to and degradation
of ECM substrates. We identiﬁed that PRL-3 expression in TNBC cells
signiﬁcantly alters TNBC cell adhesion and spreading on laminin,
which is abundantly expressed in human breast tissue. Diaz et al.
observed that out of 212 breast tumors, laminin protein staining
was present in a linear pattern surrounding all normal ducts and
lobules and around all ducts involved by ductal carcinoma in situ
(DCIS) [40]. Deposition of laminin was also found immediately ad-
jacent to invasive tumor cells and a negative correlation between
the extent of extracellular laminin deposition and ER and HER2 posi-
tivity was found [40], suggesting that peri-cellular deposition of
laminin may be higher in ER and HER2 negative tumors, such as
TNBCs. We also observed that TNBC cells were more eﬃcient at in-
vading through laminin-richMatrigel when PRL-3was overexpressed
and that this process was mediated by upregulation of MMP-10, a
key metalloproteinase with speciﬁc action on laminin. Impor-
tantly, these data also suggest that the PRL-3 ability to invoke a
migration and invasion program may be limited by the surround-
ing levels of extracellular laminin. It is therefore conceivable that
areas of “invasive heterogeneity” may exist in a tumor despite the
levels of PRL-3 expression – which may not confer an invasive ad-
vantage in areas without laminin deposition. A working model
incorporating the data presented herein is depicted in Fig. 7.
Taken together, these data provide a preliminary framework for
further analyses on the interplay between PRL-3 and the FA pathway
(Src-ERK-RhoGTPase), actin dynamics, and the relationship between
PRL-3 expression and the upregulation of MMP-10. While another
group has preliminarily reported the in vivo effects of knocking down
PRL-3 on primary TNBC tumor growth [41], studies examining the
effects of PRL-3 knock down or AMPI-109 treatment on invasive and
metastatic endpoints in TNBC animal models are urgently needed.
Our laboratory is currently pursuing these studies. Signiﬁcantly,
because AMPI-109 reduces PRL-3 levels [6], AMPI-109 treatment
or blockade of PRL-3 using selective inhibitors may be a viable strat-
egy for decreasing the metastatic potential of TNBC cells.
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